Is NMN better than NR for raising NAD+ levels?

At equivalent doses, NMN and NR raise blood NAD+ levels by similar amounts. A 2025 human trial found both approximately doubled circulating NAD+ at 1 gram per day over 14 days. However, NMN has shown efficacy at lower doses (250 mg) in multiple trials, while the strongest NR results come from studies using 500-1,000 mg. This suggests NMN may be more dose-efficient, but both compounds effectively raise NAD+.

Why does NR have FDA GRAS status but NMN does not?

NR received FDA GRAS status in 2016 largely because ChromaDex, the primary NR manufacturer, invested in the regulatory process early. GRAS status means the FDA has no objections to NR's use in certain food products at specified amounts. NMN has not gone through the same GRAS review process. In November 2022, the FDA briefly raised questions about NMN's regulatory classification, but NMN remains widely available as a dietary supplement in the United States and internationally. The absence of GRAS status does not mean NMN is unsafe — it means the specific regulatory pathway has not been completed.

Can you take NMN and NR together?

There is no published clinical evidence showing that combining NMN and NR provides additional benefits beyond taking either one alone. Since NR must be converted to NMN before becoming NAD+, taking both would be biochemically redundant — you would be supplementing with both the precursor and the precursor's precursor. Most researchers and clinicians suggest choosing one. That said, no safety concerns have been identified with combining them.

How long does it take for NMN or NR to raise NAD+ levels?

Both compounds raise NAD+ levels relatively quickly. The 2025 comparative trial showed significant NAD+ increases within 14 days for both NMN and NR at 1 gram daily. A pharmacokinetic study of NR found dose-dependent NAD+ increases within hours of a single dose, with sustained elevation over weeks. NMN trials have similarly shown elevated NAD+ within the first weeks of supplementation. Sustained benefits to physical function and metabolic health typically require 8-12 weeks of consistent supplementation based on available trial data.

Both NMN and NR have demonstrated strong safety profiles in human clinical trials. NR has been tested in more trials overall, with doses up to 2,000 mg per day showing no serious adverse events. NMN has been studied at doses up to 900 mg per day in randomized controlled trials with no serious adverse effects reported. Neither compound causes flushing — a common side effect of niacin (nicotinic acid), a different form of vitamin B3. Minor gastrointestinal discomfort has been occasionally reported with both, typically at higher doses.

What does the latest research say about NMN vs NR for anti-aging?

As of early 2026, neither NMN nor NR has demonstrated definitive anti-aging effects in a large, long-term human randomized controlled trial. Both have shown indirect markers of benefit: NAD+ elevation, improved insulin sensitivity (NMN), improved physical performance metrics (both), and cerebral NAD+ repletion in neurodegeneration (NR). A 2024 meta-analysis of NAD+ precursor trials noted that while biomarker improvements are consistent, translation to clinically meaningful anti-aging endpoints is still emerging. The field is moving rapidly, with several large trials underway for both compounds.

Are there food sources of NMN and NR?

Yes, but in very small quantities. NMN is found in edamame (~1.9 mg per 100g), broccoli (~1.1 mg per 100g), cabbage, avocado, and tomato. NR is found in milk and yeast-containing foods. These amounts are far below the 250-1,000 mg doses used in clinical trials, which is why supplementation is the primary method for meaningfully boosting NAD+ levels.

NMN vs NR: Which NAD+ Precursor Is Actually Better for Anti-Aging?

NMN vs NR is the supplement world's version of Coke vs Pepsi -- except the stakes feel higher because you're investing real money in something you can't taste, can't feel working in real-time, and won't know the full results of for years. Most people reading this just want a straight answer: which one should I take? We'll get there, and we'll give you our honest opinion. But the real answer requires a little context first, because these two molecules are more similar than the marketing wars suggest -- and the differences that do exist might not be the ones you'd expect.

A 2025 head-to-head human trial found that both NMN and NR roughly doubled circulating NAD+ after just 14 days at 1 gram per day, while nicotinamide (plain old NAM) barely moved the needle. So they both work. The question is whether the differences in how they work matter enough to tip the scales.

What Are NMN and NR?

Both NMN and NR are forms of vitamin B3, and they're both precursors to NAD+ -- the coenzyme that every cell in your body uses for energy metabolism, DNA repair, and sirtuin activation. If you're fuzzy on why NAD+ matters so much, our NAD+ explainer is worth a quick read. But here's the short version: NAD+ levels decline as you age, and that decline is linked to basically everything you associate with getting older.

NMN (Nicotinamide Mononucleotide)

NMN is the direct precursor to NAD+. Think of it as being one stop away on the subway line. The enzyme NMNAT takes NMN and converts it straight into NAD+ by attaching an adenylyl group. One step. Done.

Structurally, NMN is a nicotinamide group bonded to a ribose sugar and a phosphate group (molecular weight: 334.22 g/mol). You'll find trace amounts of it in edamame, broccoli, cabbage, cucumber, and avocado -- though you'd need to eat an absurd quantity to match the 250-500 mg doses used in clinical trials.

NR (Nicotinamide Riboside)

NR is one step further back. It's smaller than NMN -- it's missing that phosphate group (molecular weight: 255.25 g/mol) -- and it needs two enzymatic conversions to become NAD+. First, NR kinase enzymes (NRK1 or NRK2) phosphorylate NR into NMN. Then NMNAT converts that NMN into NAD+.

Read that again: NR has to become NMN before it can become NAD+. It goes through the exact same final step.

NR occurs naturally in small amounts in milk and yeast-containing foods.

So What's the Actual Difference?

The core mechanistic difference is simple: NMN is one step closer to NAD+. NR has to be converted to NMN first, adding an extra enzymatic step.

But does that automatically make NMN better? Not necessarily. Conversion speed is just one piece of the puzzle. Absorption, how efficiently your cells take it up, where it ends up in your body, and what happens to it during digestion all matter too. And as we'll see, the story gets more complicated the deeper you look.

Head-to-Head Comparison Table

Factor	NMN	NR
Full name	Nicotinamide mononucleotide	Nicotinamide riboside
Molecular weight	334.22 g/mol	255.25 g/mol
Steps to NAD+	1 (NMN > NAD+)	2 (NR > NMN > NAD+)
Key conversion enzymes	NMNAT	NRK1/NRK2, then NMNAT
Typical clinical dosage	250-500 mg/day	300-1,000 mg/day
FDA GRAS status	No (classified as supplement)	Yes (since 2016)
Published human RCTs	~20+ (as of early 2026)	~40+ (as of early 2026)
Approximate retail price	$30-80/month	$30-60/month
Cell membrane transport	Under investigation (SLC12A8 in mice)	Via equilibrative nucleoside transporters (ENTs)
Tissue reach (animal data)	Muscle, brain, adipose, liver	Primarily liver and kidney (NRK1 highest expression)

Bioavailability: How Much NAD+ Do You Actually Get?

This is the real battleground. How much of what you swallow actually ends up as usable NAD+ in your cells? The honest answer is more complicated than partisans on either side tend to admit.

What the Clinical Trials Tell Us

The most important study in this debate dropped in 2025: a randomized, double-blind trial at the University of Lausanne that gave 65 healthy adults either 1 gram of NMN, 1 gram of NR, or 1 gram of nicotinamide daily for 14 days. Both NMN and NR roughly doubled whole-blood NAD+. Nicotinamide didn't do much. This was the first proper head-to-head comparison in humans, and the takeaway was clear -- at the same dose, they're in the same ballpark.

But here's where it gets interesting.

When you look at lower doses, NMN starts to pull ahead on efficiency. A 2022 trial found that just 250 mg of NMN daily for 12 weeks raised NAD+ levels in healthy older men and improved muscle function. A 2024 multicenter trial confirmed similar NAD+ bumps at the same 250 mg dose.

NR's strongest results, on the other hand, tend to come from studies using 500-1,000 mg. A pharmacokinetic study showed that 1,000 mg of NR raised whole-blood NAD+ by about 142% over two weeks. The NR-SAFE trial in Parkinson's patients also used 1,000 mg. NR at 300 mg does show some effect, but the really convincing data clusters at the higher end.

What does this mean practically? You can likely get comparable NAD+ elevation from 250-300 mg of NMN as you'd get from 500-1,000 mg of NR. That's a meaningful difference if you're price-sensitive or prefer taking fewer pills. We should note, though, that direct dose-response comparisons within the same study are still limited -- so this is a reasonable inference from the available data, not a proven fact.

Where Does the NAD+ Actually Go?

Raising your total blood NAD+ is great, but what really matters is where that NAD+ ends up. This is where animal studies hint at some potentially important differences.

In mouse studies, NMN supplementation has raised NAD+ in skeletal muscle, brain tissue, fat tissue, and the liver. Research from Washington University School of Medicine has shown that NMN restores NAD+ in aged mouse muscle and improves mitochondrial function in brain tissue. That's a pretty broad tissue reach.

NR, meanwhile, gets processed primarily where its key conversion enzyme (NRK1) is most active -- and that's the liver and kidneys. A 2019 study confirmed the liver as a primary hub for NR processing. This doesn't mean NR can't benefit other tissues, but it may preferentially boost hepatic NAD+.

Now, a 2024 study threw a curveball at both camps: it turns out that gut bacteria partially break down both NMN and NR into nicotinic acid, which then raises NAD+ through a completely different pathway (the Preiss-Handler pathway). So some of the NAD+ boost from either supplement may actually be happening through the same backdoor mechanism. That's a humbling finding for anyone who's been making clean mechanistic arguments about either molecule.

A word of caution: Most of the tissue distribution data comes from animal studies. We have very few controlled human studies that measure NAD+ in specific tissues like muscle biopsies or cerebrospinal fluid after NMN or NR supplementation. These studies are hard to do and expensive to run. Until we have more human tissue-level data, take claims about differential tissue distribution as promising leads, not established facts.

Clinical Evidence: Who's Got the Stronger Track Record?

Let's be straightforward: NR currently has the bigger body of clinical evidence. NMN's data is promising and growing fast, but it's the younger dataset. Here's what we know about each.

NR's Research Base

With 40+ published human trials as of early 2026, NR is the most extensively studied NAD+ precursor in humans. The highlights:

Safety is well-established. NR received FDA GRAS status in 2016, and ChromaDex's Niagen product holds New Dietary Ingredient status. Doses up to 1,000 mg twice daily have been well-tolerated with no serious adverse events.
NAD+ elevation is consistent and dose-dependent. At 1,000 mg/day, expect roughly a 142% increase over two weeks.
It's been tested in real disease contexts. The NR-SAFE trial showed that 1,000 mg daily for 30 days actually increased cerebral NAD+ levels in Parkinson's patients -- one of the few studies demonstrating brain-level changes in humans. That's a big deal. There are also completed trials in peripheral artery disease (the NICE trial, 2024) and long-COVID (2025).

NMN's Research Base

NMN has around 20+ published human trials, and the pace has picked up dramatically since 2022. The standout results:

The insulin sensitivity finding. A 2021 study in Science showed that just 250 mg of NMN improved muscle insulin sensitivity in prediabetic postmenopausal women. This was the first human trial demonstrating metabolic benefits from any NAD+ precursor -- a genuine milestone.
Physical performance improvements. A 2024 systematic review of NMN trials found significant gains in walking speed and grip strength. These aren't abstract biomarkers; they're things that matter in daily life.
Reliable NAD+ elevation at lower doses. Multiple trials confirm the dose-response relationship from 250-900 mg per day, with 250 mg consistently showing efficacy.
Arterial stiffness. A 2023 trial examined long-term NMN supplementation's effects on NAD+ metabolism and arterial stiffness.
The head-to-head result. The 2025 trial showed NMN matched NR at equal doses for doubling circulating NAD+.

The Bottom Line on Evidence

NR wins on volume: more trials, more disease-specific studies, and an FDA GRAS designation. NMN wins on efficiency at lower doses and produced the first NAD+ precursor trial showing real metabolic health improvements. Neither compound has yet proven genuine anti-aging effects in a large, long-term human trial. That's the honest state of the science, and anyone telling you otherwise is getting ahead of the data.

The SLC12A8 Transporter: Does NMN Have a Secret Shortcut Into Cells?

You'll see this come up a lot in NMN marketing, so let's talk about it -- and whether you should actually care.

What Was Discovered

In 2019, Shin-ichiro Imai's team at Washington University identified a protein called SLC12A8 that appears to act as a dedicated NMN transporter in mice. The key findings: it's highly expressed in the mouse small intestine, it specifically transports NMN (not NR), it's sodium-dependent, and -- here's the interesting part -- its expression increases in aged mice, as if the body is trying to compensate for declining NAD+ by getting better at absorbing its precursor.

If this works the same way in humans, it would mean NMN has a VIP entrance into cells. NMN could waltz in intact through its own dedicated door, while NR slips through the more general equilibrative nucleoside transporters that handle lots of different molecules.

Why It's Controversial

Not everyone's buying it. A separate research group published a direct rebuttal later that year arguing the original study's methods and data didn't adequately support the NMN transport conclusion. The Imai lab has continued publishing supporting evidence, including a 2022 study linking SLC12A8 in the brain to energy metabolism and muscle function during aging. But the debate isn't settled.

Should You Care?

Honestly? Probably not much -- at least not yet. Here's why: this transporter was identified in mice, and while it appears to exist across species, nobody's demonstrated that it meaningfully changes how oral NMN supplementation works in humans. Add in the 2024 finding that gut bacteria break down both NMN and NR into nicotinic acid before some of it even reaches cells, and the neat "direct transport" story gets a lot messier.

The SLC12A8 transporter is a fascinating piece of basic science. It might eventually prove to be a real advantage for NMN. But basing your supplement decision on it today would be like buying a house because there are rumors of a new highway being built nearby. Maybe it happens, maybe it doesn't. Make your choice on what we know now, and consider it a potential bonus if the transporter story pans out.

Which Should You Choose? Our Honest Take

We sell NMN-based products, so take this with appropriate context. But we're going to give you the same advice we'd give a friend, because we think that's more useful than a sanitized marketing answer.

Go with NMN if...

You want the most NAD+ for the fewest milligrams. This is NMN's clearest advantage. Trial after trial shows meaningful NAD+ increases at 250 mg, while NR typically needs 2-4x that dose for comparable results. Our NMN dosage guide goes deeper on finding your sweet spot. If you're the kind of person who likes taking fewer capsules and spending efficiently, NMN makes a strong case.

You find the shorter conversion pathway compelling. One enzymatic step vs. two. It's an elegant argument, and the basic biochemistry checks out even if the real-world magnitude of the difference isn't fully quantified yet.

You're interested in the muscle and brain data. The animal studies showing broad tissue distribution -- particularly in skeletal muscle and brain -- are suggestive. The insulin sensitivity trial in humans adds weight. If your primary concerns are physical performance and metabolic health, NMN's dataset speaks to those outcomes more directly.

You're comfortable with a newer but rapidly maturing evidence base. NMN doesn't have as many published trials as NR, but it has enough to establish safety and efficacy, and the pace of new research is accelerating.

Dan Alchemy's NAD+ Elixir uses NMN at clinically studied doses. You can also browse our roundup of top-rated NMN supplements if you want to compare what's out there.

Go with NR if...

Regulatory track record matters to you. NR's FDA GRAS status and longer history of regulatory engagement provide a level of institutional validation that NMN hasn't pursued yet. If that kind of thing helps you sleep at night, it's a perfectly valid reason to lean NR.

You want the deepest possible pool of human data. Forty-plus trials is a lot. NR has been tested in more diverse populations and more disease contexts than NMN has. If you're the type who wants the most evidence before committing, NR is the conservative choice.

You have a specific condition that's been studied with NR. If you're dealing with Parkinson's, peripheral artery disease, or long-COVID recovery, NR has disease-specific trials that NMN simply doesn't (yet). That matters.

You prefer well-characterized cell transport. NR's entry through equilibrative nucleoside transporters is established science, not a debate.

Here's What We Actually Think

Both of these compounds work. The 2025 head-to-head trial showed that pretty clearly. The differences between them are real but smaller than the supplement industry's marketing battles would have you believe -- and much smaller than the difference between taking either one and taking nothing.

A 2025 review in Food Frontiers examining the mechanisms and clinical comparisons of both compounds concluded that more research is needed on bioavailability and pharmacokinetics for each. Translation: even the researchers who study this full-time think the jury's still out on which is definitively better.

Our lean is toward NMN, primarily because of the dose efficiency advantage and the metabolic health data. But if someone told us they were taking NR instead, we wouldn't try to talk them out of it. You're making a good choice either way. The best NAD+ precursor is the one you'll actually take consistently, at a dose that's supported by clinical evidence, from a manufacturer you trust.

Sources

Imai, S. et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism, 2019. PubMed
Schmidt, M.S. & Brenner, C. "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter." Nature Metabolism, 2019. Nature
Airhart, S.E. et al. "An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers." PLOS ONE, 2017. PLOS ONE
Martens, C.R. et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 2018. Nature
Conze, D. et al. "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults." Scientific Reports, 2019. Nature
Brakedal, B. et al. "NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease." Nature Communications, 2023. Nature
Yoshino, M. et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021.
Yi, L. et al. "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, 2023. PMC
Igarashi, M. et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." NPJ Aging, 2022. PMC
Reiten, O.K. et al. "Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide." Aging Cell, 2021. PMC
Pencina, K.M. et al. "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation." Scientific Reports, 2023. Nature
Lapatto, H.A.K. et al. "Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation." Science Advances, 2024. Science
Yang, Y. et al. "An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR)." Food Frontiers, 2025. Wiley
Tsilioni, I. et al. "Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage." Nature Communications, 2019. Nature
FDA GRAS Notice 635: Nicotinamide riboside chloride. FDA
Denk, D. et al. "Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial." Nature Communications, 2024. Nature

This article is for informational purposes only and does not constitute medical advice. The statements in this article have not been evaluated by the Food and Drug Administration. NAD+ precursor supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any new supplement regimen, especially if you have existing health conditions or are taking medications. Dan Alchemy is a retailer of NMN-based supplements and has a commercial interest in this space, which we disclose in the interest of transparency.